Real-world Patient Reported Outcomes Among Patients Treated With Camzyos
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorBristol-Myers Squibb
About this trial
This real-world study will assess changes in health status among participants with symptomatic obstructive hypertrophic cardiomyopathy who are treated with mavacamten in the real world.
Eligibility criteria
Qualifiers
Participants ≥18 years of age.
Participants who are prescribed mavacamten for obstructive hypertrophic cardiomyopathy
Provided informed consent to participate in the study
Disqualifiers
Previously or currently enrolled in clinical trials for any cardiac myosin inhibitors
Treated for >7 days with mavacamten by the day of completing the baseline survey
Enrolled in any clinical trials at the time of or within the six-month period prior to the screening
Had heart attack requiring coronary artery bypass grafting within the three-month period prior to the screening
Trial design
Treatments tested in this trial
- Mavacamten
Treatment groups
118 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov